These tools will no longer be maintained as of December 31, 2024. Archived website can be found here. PubMed4Hh GitHub repository can be found here. Contact NLM Customer Service if you have questions.


BIOMARKERS

Molecular Biopsy of Human Tumors

- a resource for Precision Medicine *

165 related articles for article (PubMed ID: 2633575)

  • 81. Aberrant seasonal variations of platelet serotonin uptake in endogenous depression.
    Malmgren R; Aberg-Wistedt A; Mårtensson B
    Biol Psychiatry; 1989 Feb; 25(4):393-402. PubMed ID: 2930808
    [TBL] [Abstract][Full Text] [Related]  

  • 82. Alteration by a plasma factor(s) of platelet aggregation in unmedicated unipolar depressed patients.
    Nugent DF; Dinan TG; Leonard BE
    J Affect Disord; 1994 May; 31(1):61-6. PubMed ID: 8046161
    [TBL] [Abstract][Full Text] [Related]  

  • 83. [A clinico-biological study of the thrombocyte serotonin-transport complex in therapeutically resistant patients with endogenous depression undergoing combined treatment].
    Brusov OS; Panteleeva GP; Bondar' VV; Dikaia VI; Faktor MI; Zlobina GP; Pavlova OA; Abrosimov NV; Lideman RR
    Vestn Ross Akad Med Nauk; 1996; (4):29-32. PubMed ID: 8754076
    [TBL] [Abstract][Full Text] [Related]  

  • 84. Alteration by a plasma factor of platelet aggregation and 5HT uptake in depression.
    McAdams C; Colohan FJ; Brophy J; Leonard BE
    Biol Psychiatry; 1992 Aug; 32(3):296-8. PubMed ID: 1420645
    [No Abstract]   [Full Text] [Related]  

  • 85. The effect of escitalopram on platelet activity.
    Canan F; Ataoglu A
    Thromb Res; 2011 Jan; 127(1):57. PubMed ID: 20709365
    [No Abstract]   [Full Text] [Related]  

  • 86. Uncoupler-accelerated efflux of 5-hydroxytryptamine from platelets of healthy subjects and patients with unipolar and bipolar depression.
    Peterson LL; Bartfai T; Ernster L; Wickström G; Roos BE; Wehlin-Ahs U; Agren H
    Psychiatry Res; 1984 Oct; 13(2):141-50. PubMed ID: 6596581
    [TBL] [Abstract][Full Text] [Related]  

  • 87. Variations in platelet 5-hydroxytryptamine in control and depressed populations.
    Healy D; O'Halloran A; Carney PA; Leonard BE
    J Psychiatr Res; 1986; 20(4):345-53. PubMed ID: 3806429
    [TBL] [Abstract][Full Text] [Related]  

  • 88. Monoamine-related markers of depression: changes following treatment.
    Healy D; Carney PA; Leonard BE
    J Psychiatr Res; 1982-1983; 17(3):251-60. PubMed ID: 6821276
    [TBL] [Abstract][Full Text] [Related]  

  • 89. [Platelet serotonin in endogenous depressive patients and normal controls].
    Spatz H; Spatz N
    Acta Psiquiatr Psicol Am Lat; 1995 Sep; 41(3):230-6. PubMed ID: 8728799
    [TBL] [Abstract][Full Text] [Related]  

  • 90. Plasma free 5HT and platelet 5HT in depression: case-control studies and the effect of antidepressant therapy.
    Sarrias MJ; Martínez E; Celada P; Udina C; Alvarez E; Artigas F
    Adv Exp Med Biol; 1991; 294():653-8. PubMed ID: 1722955
    [No Abstract]   [Full Text] [Related]  

  • 91. [The biological evaluation of depression severity: a novel method for the determination of platelet serotonin concentration].
    Bezrukov MV; Shilov IuE; Shestakova NV; Kliushnik TP
    Zh Nevrol Psikhiatr Im S S Korsakova; 2014; 114(8):51-7. PubMed ID: 25345631
    [TBL] [Abstract][Full Text] [Related]  

  • 92. An open study of oral flesinoxan, a 5-HT1A receptor agonist, in treatment-resistant depression.
    Grof P; Joffe R; Kennedy S; Persad E; Syrotiuk J; Bradford D
    Int Clin Psychopharmacol; 1993; 8(3):167-72. PubMed ID: 8263314
    [TBL] [Abstract][Full Text] [Related]  

  • 93. [Levels of intra- and extra-platelet 5-HT-analogous substances and the effect of 5-HT on platelet aggregation in acute myocardial infarction].
    Xia Y; Dai GZ; Zhou BC
    Zhonghua Xin Xue Guan Bing Za Zhi; 1987 Apr; 15(2):83-5, 127. PubMed ID: 3622261
    [No Abstract]   [Full Text] [Related]  

  • 94. The platelet intracellular calcium response to serotonin in subsyndromal depression.
    Berk M; Mitchell VS; Plein H
    Int Clin Psychopharmacol; 1998 May; 13(3):107-10. PubMed ID: 9690976
    [TBL] [Abstract][Full Text] [Related]  

  • 95. Sustained antidepressant effect of PEA replacement.
    Sabelli H; Fink P; Fawcett J; Tom C
    J Neuropsychiatry Clin Neurosci; 1996; 8(2):168-71. PubMed ID: 9081552
    [TBL] [Abstract][Full Text] [Related]  

  • 96. [A comparative study of befol pharmacokinetics in experimental animals and man].
    Rodionov AP; Ignatova NA; Kushnarev VV; Muzychenko AP
    Farmakol Toksikol; 1990; 53(2):62-3. PubMed ID: 2369959
    [TBL] [Abstract][Full Text] [Related]  

  • 97. Evaluation of peripheral serotonin content and α
    Aleksovski B; Novotni A; Vujović V; Rendevski V; Manusheva N; Neceva V; Filipce A; Risteski A; Aleksovski V; Gjorgoski I
    Int J Psychiatry Clin Pract; 2018 Sep; 22(3):215-224. PubMed ID: 29216784
    [TBL] [Abstract][Full Text] [Related]  

  • 98. Platelet alpha-adrenergic receptors in depression: ligand binding and aggregation studies.
    Wood K; Swade C; Coppen A
    Acta Pharmacol Toxicol (Copenh); 1985; 56 Suppl 1():203-11. PubMed ID: 2984889
    [No Abstract]   [Full Text] [Related]  

  • 99. [Comorbidity of depressive disorders and coronary heart disease: general aspects of pathogenesis].
    Neznanov NG; Kozlova SN; Mazo GE; Shlyakhto NG; Smirnov BI
    Zh Nevrol Psikhiatr Im S S Korsakova; 2015; 115(5):20-26. PubMed ID: 26356156
    [TBL] [Abstract][Full Text] [Related]  

  • 100. Serotonin (5-HT) receptor, 5-HT transporter and G protein-effector expression: implications for depression.
    Lesch KP; Aulakh CS; Wolozin BL; Murphy DL
    Pharmacol Toxicol; 1992; 71 Suppl 1():49-60. PubMed ID: 1480560
    [No Abstract]   [Full Text] [Related]  

    [Previous]   [Next]    [New Search]
    of 9.